Last $3.28 USD
Change Today -0.0399 / -1.20%
Volume 5.5K
NVGN On Other Exchanges
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

novogen limited-spons adr (NVGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/25/13 - $6.84
52 Week Low
08/8/14 - $2.72
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

novogen limited-spons adr (NVGN) Related Businessweek News

No Related Businessweek News Found

novogen limited-spons adr (NVGN) Details

Novogen Limited operates as a pharmaceutical drug development company worldwide. It focuses on the development of a family of anti-cancer drugs based on super-benzopyran and stealth drug technologies. The company’s lead drug candidate is CS-6, a mitochondrial electron transfer inhibitor for the treatment of temozolomide-resistant glioblastoma multiforme and late-stage chemo-refractory ovarian cancer. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.

Founded in 1994

novogen limited-spons adr (NVGN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: A$332.8K
Company Secretary
Total Annual Compensation: A$57.5K
Vice-President of Drug Discovery, Manufacture...
Total Annual Compensation: A$279.0K
Director of ATM Program
Total Annual Compensation: A$52.5K
Chief Scientific Officer
Total Annual Compensation: A$200.0K
Compensation as of Fiscal Year 2014.

novogen limited-spons adr (NVGN) Key Developments

Novogen Limited - Special Call

To review strategies for R&D, clinical trials and company growth

Novogen Limited, Special/Extraordinary Shareholders Meeting, Aug 13, 2014

Novogen Limited, Special/Extraordinary Shareholders Meeting, Aug 13, 2014., at 14:00 AUS Eastern Standard Time. Location: AT THE OFFICES OFCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED. Agenda: To consider subsequent approval of issues of conversion shares; to consider approval of issue of new shares and attaching warrants; and to transact any other business as may be brought before the Meeting.

Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed against Chemo-Resistant Ovarian Cancer Stem Cells

Novogen Limited and CanTx Inc., its joint venture with Yale University announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity. Based on the potency seen in animal models to date, and the potential to prevent recurrence, Novogen and CanTx believe that Intra-Peritoneal Trx-1 could be utilized as a first-line therapy for ovarian cancer. Trx-1 is being developed for the treatment of ovarian cancer, particularly for its ability to kill chemo-resistant ovarian cancer stem cells. Novogen and CanTx plan to file an Investigational New Drug application (IND) with the FDA in early 2015 and to start a Phase 1 study by mid-2015. The data presented on June 17, 2014 shows that Trx-1 can significantly retard the growth of highly chemo-resistant, human ovarian cancer stem cells in an animal model considered to be highly representative of the human situation. The animal model developed at Yale involves injecting human CD44+/MyD88+ (cancer stem) cells into the peritoneal cavity of mice, where they quickly establish highly aggressive multiple tumors comprising both CD44+/MyD88+ cells and recurrent CD44-/MyD88- cells, all highly chemo-resistant. This animal model is representative of the human situation where ovarian cancer generally is confined to the abdomen and the cells are free to spread, leading to multiple tumors often involving dozens or even hundreds of individual tumors. Faced with the challenge of treating such scattered tumor load, the injection of anti-cancer drugs directly into peritoneal cavity is an approach clinicians have long considered.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVGN:US $3.28 USD -0.0399

NVGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVGN.
View Industry Companies

Industry Analysis


Industry Average

Valuation NVGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 58.5x
Price/Book 16.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 46.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOGEN LIMITED-SPONS ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at